Aspire Biopharma Files S-1 for Public Offering

Ticker: ASBPW · Form: S-1 · Filed: May 13, 2025 · CIK: 1847345

Aspire Biopharma Holdings, INC. S-1 Filing Summary
FieldDetail
CompanyAspire Biopharma Holdings, INC. (ASBPW)
Form TypeS-1
Filed DateMay 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: ipo, pharmaceutical, sec-filing

TL;DR

Aspire Biopharma (fka PowerUp Acquisition Corp.) just filed its S-1, prepping for an IPO. Get ready for pharma news.

AI Summary

Aspire Biopharma Holdings, Inc. filed an S-1 form on May 13, 2025, indicating its intention to become a publicly traded company. The company, previously known as PowerUp Acquisition Corp., is based in Humacao, Puerto Rico, and operates in the pharmaceutical preparations sector. This filing marks a significant step in their journey to raise capital and expand their operations.

Why It Matters

This S-1 filing signals Aspire Biopharma's move towards public trading, potentially opening up new avenues for funding and growth in the competitive pharmaceutical industry.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Aspire Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for companies in this sector.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Aspire Biopharma Holdings, Inc.?

Aspire Biopharma Holdings, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.

When was this S-1 filing submitted to the SEC?

The S-1 filing was submitted on May 13, 2025.

What was the company's former name?

The company was formerly known as PowerUp Acquisition Corp.

Where is Aspire Biopharma Holdings, Inc. located?

The company's business and mailing address is 194 Candelaro Drive, #233, Humacao, PR 00791.

What is the SEC file number associated with this S-1 filing?

The SEC file number for this filing is 333-287240.

Filing Details

This Form S-1 (Form S-1) was filed with the SEC on May 13, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).

View full filing on EDGAR

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing